Literature DB >> 8179578

Coronary atherosclerotic smooth muscle cells overexpress human parathyroid hormone-related peptides.

T Nakayama1, A Ohtsuru, H Enomoto, H Namba, S Ozeki, Y Shibata, T Yokota, M Nobuyoshi, M Ito, I Sekine.   

Abstract

Parathyroid hormone-related peptide (PTHrP) was originally characterized as a tumor product responsible for hypercalcemia of malignancy and was subsequently found to be produced in many normal tissues. PTHrP is now suggested to play a critical role in the local modulation of vascular smooth muscle function. To elucidate the involvement of PTHrP in coronary atherosclerosis, we immunohistochemically examined coronary arteries obtained from 76 patients with various grades of atherosclerosis and compared the correlation between PTHrP staining and the percent stenosis. Smooth muscle cells at sites of coronary atherosclerosis overexpressed PTHrP, while cells from normal coronary arteries did not. The in situ hybridization using PTHrP riboprobe has also proven the overexpression of PTHrPmRNA in the affected lesions following atherectomy. The intensity of PTHrP expression by smooth muscle cells was significantly correlated with the degree of coronary artery stenosis. Coronary arterial PTHrP overexpression is closely related to the severity and/or progression of coronary atherosclerosis.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8179578     DOI: 10.1006/bbrc.1994.1553

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  8 in total

1.  Reduced coronary flow reserve in patients with primary hyperparathyroidism: a study by G-SPECT myocardial perfusion imaging.

Authors:  Cecilia Marini; Massimo Giusti; Riccardo Armonino; Giorgio Ghigliotti; GianPaolo Bezante; Lara Vera; Silvia Morbelli; Elena Pomposelli; Michela Massollo; Patrizia Gandolfo; Francesco Minuto; Gianmario Sambuceti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-09-04       Impact factor: 9.236

Review 2.  Parathyroid-hormone-related peptides. A new class of multifunctional proteins.

Authors:  T Roskams; V Desmet
Journal:  Am J Pathol       Date:  1997-03       Impact factor: 4.307

3.  EBP50 inhibits the anti-mitogenic action of the parathyroid hormone type 1 receptor in vascular smooth muscle cells.

Authors:  Gyun Jee Song; Stacey Barrick; Kristen L Leslie; Brian Sicari; Nathalie M Fiaschi-Taesch; Alessandro Bisello
Journal:  J Mol Cell Cardiol       Date:  2010-09-16       Impact factor: 5.000

Review 4.  Parathyroid hormone-related protein and its receptors: nuclear functions and roles in the renal and cardiovascular systems, the placental trophoblasts and the pancreatic islets.

Authors:  T L Clemens; S Cormier; A Eichinger; K Endlich; N Fiaschi-Taesch; E Fischer; P A Friedman; A C Karaplis; T Massfelder; J Rossert; K D Schlüter; C Silve; A F Stewart; K Takane; J J Helwig
Journal:  Br J Pharmacol       Date:  2001-11       Impact factor: 8.739

Review 5.  A transgenic mouse model for studying the role of the parathyroid hormone-related protein system in renal injury.

Authors:  Ricardo J Bosch; Arantxa Ortega; Adriana Izquierdo; Ignacio Arribas; Jordi Bover; Pedro Esbrit
Journal:  J Biomed Biotechnol       Date:  2010-10-31

Review 6.  [Atherosclerosis and uremia: signifance of non-traditional risk factors].

Authors:  Walter H Hörl
Journal:  Wien Klin Wochenschr       Date:  2003-04-30       Impact factor: 1.704

7.  Endogenous parathyroid hormone-related protein regulates the expression of PTH type 1 receptor and proliferation of vascular smooth muscle cells.

Authors:  Gyun Jee Song; Nathalie Fiaschi-Taesch; Alessandro Bisello
Journal:  Mol Endocrinol       Date:  2009-07-02

8.  Heart ventricular activation in VAT difference maps from children with chronic kidney disease.

Authors:  Krystyna Laszki-Szcząchor; Dorota Polak-Jonkisz; Danuta Zwolińska; Lesław Rusiecki; Anna Janocha; Małgorzata Sobieszczańska
Journal:  Pediatr Nephrol       Date:  2011-08-11       Impact factor: 3.714

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.